Results 181 to 190 of about 144,829 (355)

Imidazolium-tagged glycan probes for non-covalent labeling of live cells

, 2016
David Benito‐Alifonso, Shirley Tremel, Joanna C. Sadler, Dominic W. Berry, M. Carmen Galán   +4 more
openalex   +2 more sources

Galectin-Glycan Interactions as Regulators of B Cell Immunity [PDF]

, 2018
Nicholas Giovannone, Logan K. Smith, Bebhinn Treanor, Charles J. Dimitroff   +3 more
openalex   +1 more source

Interpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 IWGT quantitative analysis expert working group meeting

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Quantitative risk assessments of chemicals are routinely performed using in vivo data from rodents; however, there is growing recognition that non‐animal approaches can be human‐relevant alternatives. There is an urgent need to build confidence in non‐animal alternatives given the international support to reduce the use of animals in toxicity ...
Marc A. Beal, Guangchao Chen, Kerry L. Dearfield, Min Gi, Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Alexandra S. Long, David P. Lovell, Barbara L. Parsons, Stefan Pfuhler, John Wills, Andreas Zeller, George Johnson, Paul A. White   +14 more
wiley   +1 more source

GlyContact analyzes glycan 3D structures at scale. [PDF]

Nat Commun
Thomès L, Joeres R, Akdeniz Z, Bojar D.
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Optimizing the preparation of labeled N-glycans for rapid, simplified, and high-precision analysis. [PDF]

PLoS One
Makino R, Natsuka S.
europepmc   +1 more source

Membrane Environment Can Enhance the Interaction of Glycan Binding Protein to Cell Surface Glycan Receptors

, 2014
Lei Shen, Yini Wang, Chia-I Lin, Hung‐Wen Liu, Athena Guo, Xiaoyang Zhu   +5 more
openalex   +1 more source

A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors

Exploration, EarlyView.
We developed a spatiotemporal targeting oncolytic bacterial therapy system, the STEPT (spatiotemporal targeting EcN‐pfo terminator) system, which injects azide hyaluronic acid hydrogel into tumors to capture DBCO‐labeled engineered Escherichia coli Nissle 1917 (EcN).
Yu‐Jia Wang, Wen‐Jie Jiang, Hua‐Jun Zhao, Jian‐Qun Deng, Yi‐Min Cai, Yi Li, Xiao‐Lin Meng, Jin Hou, Feng‐Shan Wang, Ju‐Zheng Sheng   +9 more
wiley   +1 more source

GlycoGenius: a streamlined high-throughput glycan composition identification tool. [PDF]

Nat Commun
Loponte HF, Zheng J, Ding Y, Oliveira IA, Basse K, Todeschini AR, Horvatovich PL, Lageveen-Kammeijer GSM.   +7 more
europepmc   +1 more source

Substrate specificity of rat liver cytosolic α‐d‐mannosidase Novel degradative pathway for oligomannosidic type glycans [PDF]

, 1991
J.F. Haeuw, Gérard Strecker, Jean‐Michel Wieruszeski, Jean Montreuil, Jean‐Claude Michalski   +4 more
openalex   +1 more source